These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25857341)

  • 21. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects.
    Palmer AM
    Trends Pharmacol Sci; 2011 Mar; 32(3):141-7. PubMed ID: 21256602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current therapeutic strategy in Alzheimer's disease.
    Singh S; Kushwah AS; Singh R; Farswan M; Kaur R
    Eur Rev Med Pharmacol Sci; 2012 Nov; 16(12):1651-64. PubMed ID: 23161037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease.
    Williams BJ; Eriksdotter-Jonhagen M; Granholm AC
    Prog Neurobiol; 2006 Oct; 80(3):114-28. PubMed ID: 17084014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effects of flavonoids against Alzheimer's disease-related neural dysfunctions.
    Bakhtiari M; Panahi Y; Ameli J; Darvishi B
    Biomed Pharmacother; 2017 Sep; 93():218-229. PubMed ID: 28641164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
    Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
    J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Rationale for Insulin Therapy in Alzheimer's Disease.
    Ribarič S
    Molecules; 2016 May; 21(6):. PubMed ID: 27240327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug therapy strategies in Alzheimer's disease].
    Lacomblez L
    Rev Prat; 1998 Nov; 48(17):1913-7. PubMed ID: 9854394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease.
    Calabrese V; Butterfield DA; Stella AM
    Ital J Biochem; 2003 Dec; 52(4):177-81. PubMed ID: 15141484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease.
    Venigalla M; Sonego S; Gyengesi E; Sharman MJ; Münch G
    Neurochem Int; 2016 May; 95():63-74. PubMed ID: 26529297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.
    Rother M; Erkinjuntti T; Roessner M; Kittner B; Marcusson J; Karlsson I
    Dement Geriatr Cogn Disord; 1998 Jul; 9 Suppl 1():36-43. PubMed ID: 9716243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success.
    Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R
    Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update.
    de Freitas Silva M; Dias KST; Gontijo VS; Ortiz CJC; Viegas C
    Curr Med Chem; 2018; 25(29):3491-3525. PubMed ID: 29332563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies.
    McGuire MJ; Ishii M
    Cell Mol Neurobiol; 2016 Mar; 36(2):203-17. PubMed ID: 26993509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond amyloid: the future of therapeutics for Alzheimer's disease.
    Lane RF; Shineman DW; Steele JW; Lee LB; Fillit HM
    Adv Pharmacol; 2012; 64():213-71. PubMed ID: 22840749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease-modifying therapies in Alzheimer's disease.
    Salloway S; Mintzer J; Weiner MF; Cummings JL
    Alzheimers Dement; 2008 Mar; 4(2):65-79. PubMed ID: 18631951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.